Spyre Therapeutics launches SPY772 program and Phase 2 trial in HS

August 10, 2026 8:00 AM

Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced the launch of its SPY772 combination program and the initiation of a Phase 2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found